Greenbrook TMS Inc., together with its subsidiaries, controls and operates a network of outpatient mental health services centers in the United States. Its centers specialize in the provision of transcranial magnetic stimulation (TMS) therapy, an FDA-cleared non-invasive therapy for the treatment of major depressive disorder and other mental health disorders, as well as related psychiatric services. As of December 31, 2021, the company operated 94 wholly owned and 55 TMS centers in the commonwealth of Virginia and the States of Maryland, Delaware, North Carolina, Missouri, Illinois, Ohio, Texas, Connecticut, Florida, South Carolina, Michigan, Alaska, Oregon, California, Iowa, and Massachusetts. Greenbrook TMS Inc. was founded in 2011 and is headquartered in Toronto, Canada.

Greenbrook TMS Inc.

Greenbrook provides FDA-cleared TMS therapy and FDA-approved intranasal esketamine for depression treatment. Self-described as specialists in depression care.

GTMS

TSX:GTMS

Greenbrook

Last Close

1.15

13/03 19:59

Market Cap

28.55M

Beta: 1.79

Volume Today

16.73K

Avg: 9.04K

PE Ratio

−0.16

PFCF: −1.59

Financials Not Available